Secukinumab
Top View
- Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: a Randomised, Double-Blind, Placebo-Controlled Trial
- Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities
- Immunosuppressive Drugs and COVID-19: a Review
- INN Working Document 05.179 Update 2011
- A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
- 211 the Impact of Biological Interventions on Health-Related Quality of Life in Adults with Crohn's Disease
- What Is Cosentyx® (Secukinumab)?
- Recent Biotherapies and Infections
- (INN) for Biological and Biotechnological Substances
- CERTOLIZUMAB PEGOL (Cimzia®) and SECUKINUMAB (Cosentyx® )
- EAACI IG Biologicals Task Force Paper on the Use of Biologic Agents in Allergic Disorders O
- Cosentyx (Secukinumab)
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Information for the User Cosentyx® 150 Mg Solution for Injection in Pre
- Secukinumab Is Superior to Ustekinumab in Clearing Skin Of
- Secukinumab Emerges As a Rapidly Effective Therapy for Pityriasis Rubra Pilaris
- Cosentyx, INN-Secukinumab
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances